1. Anderson JR, Barr FG, Hawkins DS, Parham DM, Skapek SX, Triche TJ (2010) Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature. J Clin Oncol Off J Am Soc Clin Oncol 28:e587–e588; author reply e589-590.
https://doi.org/10.1200/JCO.2010.30.5466
2. Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, Parham DM, Teot LA, Wharam MD, Breneman JC, Donaldson SS, Anderson JR, Meyer WH (2009) Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children’s oncology group study D9803. J Clin Oncol Off J Am Soc Clin Oncol 27:5182–5188.
https://doi.org/10.1200/JCO.2009.22.3768
3. Biegel JA, Meek RS, Parmiter AH, Conard K, Emanuel BS (1991) Chromosomal translocation t(1;13)(p36;q14) in a case of rhabdomyosarcoma. Genes Chromosomes Cancer 3(6):483–484.
https://doi.org/10.1002/gcc.2870030612
4. Bisogno G, De Salvo GL, Bergeron C, Carli M, Ferrari S, Jenney M, Mercks H, Kelsey A, Gallego S, Chisholm J, Orbach D, Martelli AM, Oberlin O, Stevens M (2014) The role of doxorubicin in the treatment of rhabdomyosarcoma: preliminary results from the EpSSG RMS2005 randomized trial. Pediatr Blood Cancer 61(issue S2): abstract O-105
5. Bisogno G, Mattke A, Koscielniak E, Bergeron C, Jenney M, Knietig R, Gallego S, Schuck A, Martelli AM, Alaggio R, Rosolen A, Carli M, Oberlin O, Stevens M, Treuner J (2005) A new stratification for the first pan-European protocol for localized rhabdomyosarcoma. Sarcoma 9:abstract O 08